New Zealand - English - Medsafe (Medicines Safety Authority)

leo pharma limited - betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone;  ; calcipotriol 50 µg/g (as calcipotriol hydrate 52.2µg/g) - topical ointment - 50µg/500µg/g - active: betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone   calcipotriol 50 µg/g (as calcipotriol hydrate 52.2µg/g) excipient: ceteareth-15 dl-alpha tocopherol liquid paraffin white soft paraffin

New Zealand - English - Medsafe (Medicines Safety Authority)

leo pharma limited - betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone;  ; calcipotriol monohydrate 52.2 µg/g equivalent to 50 µg/g calcipotriol - foam - active: betamethasone dipropionate 643 µg/g equivalent to 500 µg/g betamethasone   calcipotriol monohydrate 52.2 µg/g equivalent to 50 µg/g calcipotriol excipient: butane liquid paraffin methyl ether polyoxypropylene monostearyl ether tocoferols white soft paraffin - topical treatment of psoriasis vulgaris in adults.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 ml - betamethasone dipropionate lotion (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. betamethasone dipropionate lotion (augmented), 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. risk summary there are no available data on betamethasone dipropionate lotion (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women that betamethasone dipropionate lotion (augmented) may increase the risk of having a low birthweight infant and to use betamethasone dipropionate lotion (augmented) on the sm

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

versapharm incorporated - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone dipropionate lotion usp (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. betamethasone dipropionate lotion usp (augmented), 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. risk summary there are no available data on betamethasone dipropionate lotion usp (augmented), 0.05% use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women that betamethasone dipropionate lotion usp (augmented), 0.05% may increase the risk of having a low birthweight infant and to use betamethasone dipr

United States - English - NLM (National Library of Medicine)

nucare pharamceuticals,inc. - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole 10 mg in 1 g - clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum, trichophyton mentagrophytes, and trichophyton rubrum in patients 17 years and older. none. teratogenic effects pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant rats with intravaginal doses up to 100 mg/kg (15 times the maximum

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole 10 mg in 1 g - clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum, trichophyton mentagrophytes, and trichophyton rubrum in patients 17 years and older. none. teratogenic effects pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant rats with intravaginal doses up to 100 mg/kg (15 times the maximum

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole and betamethasone dipropionate cream usp, 1%/0.05% (base) is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum , trichophyton mentagrophytes , and trichophyton rubrum in patients 17 years and older. none. teratogenic effects, pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream usp, 1%/0.05% (base) in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream usp, 1%/0.05% (base) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum, trichophyton mentagrophytes, and trichophyton rubrum in patients 17 years and older. none. teratogenic effects pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant rats with intravaginal doses up to 100 mg/kg (15 times the maximum

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum, trichophyton mentagrophytes, and trichophyton rubrum in patients 17 years and older. none. teratogenic effects pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant rats with intravaginal doses up to 100 mg/kg (15 times the maximum